AstraZeneca inks cancer deals with Bind Therapeutics, Horizon Discovery

AstraZeneca ($AZN) forged two oncology development deals on either side of the Atlantic. It teamed up with the U.K.'s Horizon Discovery on a program to target K-Ras mutant tumors, and tapped Bind Therapeutics for its nanotech cancer treatment.  Report | Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.